ID: ALA5270013

Max Phase: Preclinical

Molecular Formula: C21H22F2N3O9P

Molecular Weight: 529.39

Representations

Canonical SMILES:  CCC(=O)Nc1ccn([C@@H]2O[C@@H]3COP(=O)(OCC(=O)OCc4ccccc4)O[C@H]3C2(F)F)c(=O)n1

Standard InChI:  InChI=1S/C21H22F2N3O9P/c1-2-16(27)24-15-8-9-26(20(29)25-15)19-21(22,23)18-14(34-19)11-32-36(30,35-18)33-12-17(28)31-10-13-6-4-3-5-7-13/h3-9,14,18-19H,2,10-12H2,1H3,(H,24,25,27,29)/t14-,18-,19-,36?/m1/s1

Standard InChI Key:  GANSGCHWTJNYMB-RGYFBUTASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 529.39

Molecular Weight (Monoisotopic): 529.1062

AlogP: 2.41

#Rotatable Bonds: 8

Polar Surface Area: 144.28

Molecular Species: NEUTRAL

HBA: 11

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.37

CX Basic pKa:

CX LogP: 1.66

CX LogD: 1.66

Aromatic Rings: 2

Heavy Atoms: 36

QED Weighted: 0.40

Np Likeness Score: -0.30

References

1. Zhang L, Qi K, Xu J, Xing Y, Wang X, Tong L, He Z, Xu W, Li X, Jiang Y..  (2023)  Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.,  66  (6): [PMID:36867101] [10.1021/acs.jmedchem.3c00006]

Source

Source(1):

• Scientific Literature